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The blood brain barrier (BBB) poses a problem to deliver drugs for brain malignancies and neurodegenerative
disorders. Stem cells such as neural stem cells (NSCs) and mesenchymal stem cells (MSCs) can be used to delivery
drugs or RNA to the brain. This use of methods to bypass the hurdles of delivering drugs across the BBB is
particularly important for diseases with poor prognosis such as glioblastoma multiforme (GBM). Stem cell treatment
to deliver drugs to neural tumors is currently in clinical trial. This method, albeit in the early phase, could be an
advantage because stem cells can cross the BBB into the brain. MSCs are particularly interesting because to date,
the experimental and clinical evidence showed ‘no alarm signal’ with regards to safety. Additionally, MSCs do not
form tumors as other more primitive stem cells such as embryonic stem cells. More importantly, MSCs showed
pathotropism by migrating to sites of tissue insult. Due to the ability of MSCs to be transplanted across allogeneic
barrier, drug-engineered MSCs can be available as off-the-shelf cells for rapid transplantation. This review discusses
the advantages and disadvantages of stem cells to deliver prodrugs, genes and RNA to treat neural disorders.
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The BBB seems to be a major limitation for drugs to enter
the brain. Stem cells can home to the brain. Thus, these
cells can be the future form of treatment to bypass the
BBB. At this time, any drug could be delivered with stem
cells. The challenge will be to ensure that the stem cells
can enter the brain without the eventual inflammation
due to allogeneic responses. Since stem cells can respond
to its microenvironment to undergo differentiation, this
could be another challenge to ensure that after drug deli-
very the stem cells do not form a specialized cells within
the brain. Since there are ongoing trials, it is presumed
that the method would be improved for approved trials to
treat any brain disorder.
Introduction
The current standard of care for glioblastoma multiforme
(GBM) uses temozolomide (TMZ)-based chemotherapy
in conjunction with radiotherapy. Despite this type of
aggressive treatment, patients are faced with high morta-
lity, morbidity, cancer recurrence and short median* Correspondence: rameshwa@njms.rutgers.edu
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in any medium, provided the original work is psurvival. Current limitations in the treatment of GBM
involve obstacles towards achieving complete tumor
resection, difficulties in penetrating the blood brain barrier
(BBB), insufficient accumulation of therapeutic agents at
the site of the tumor, and tumor resistance. Thus, patients
with GBM can benefit from alternative treatments with
drug-loaded stem cells. Mesenchymal stem cells (MSCs)
and neural stem cells (NSCs) have been shown to poten-
tial efficacious cells as alternative to drug delivery to
GBM. Although this review discusses the use of stem cells
for GBM, a similar approach can be applied for other
neurological disorders. The approaches discussed in this
review will depend on further studies to determine how
the transplanted stem cells and the released therapeutic
agents will affect normal brain functions.Neurodegeneration and neurotoxicity
A major setback for drugs intended for brain disorders
is the inability to access the brain due to the surroun-
ding BBB, which prevents crossing of large hydrophilic
substances to the brain [1]. The nervous system has a
vital role to send and receive electrochemical signals for
organs to communicate. However, this communication
can become dysfunctional as would occur in neuro-
degenerative diseases and brain injury. The importancean Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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develop therapies and more importantly, to identify how
treatments such as stem cell-mediated delivery of drugs
could be effective.
Neurotoxicity is a major limitation for the develop-
ment of drugs that target the brain. A neural-targeted
drug should not cause pathology such as changes in the
expression of particular genes that could cause an
increase in intracellular proteins. An understanding of
these dysfunctions is needed to develop treatments for
stem cell delivery to the brain.
Neural dysfunction in Alzheimer’s disease (AD) has
been associated with the accumulations of hyperpho-
sphorylated tau protein and amyloid beta aggregations,
commonly referred to as neurofibrillary tangles and amy-
loid beta plaques, respectively [2]. The amyloid precursor
protein (APP) can be cleaved by alpha or beta secretase.
Under normal conditions, the precursor protein can be
cleaved by alpha secretase into two subsequent strands,
the soluble form of the precursor protein fragment and a
membrane bound fragment (C83). Alternatively, the pre-
cursor protein may be cleaved by beta secretase, resulting
in the production of a shorter soluble fragment (C99). In
AD, it has been suggested that excessive amounts of the
40 and 42 amino acid peptides resulted in the latter aggre-
gating to cause toxicity to surrounding neural tissue [3].
The accumulation of amyloid beta protein can be neuro-
trophic for undifferentiated hippocampal neurons and at
high concentrations, neurotoxic to mature neurons [4].
The neurotoxicity is caused by axonal retraction of the dif-
ferentiated neurons, resulting in cell death. Interestingly, a
common region within the amyloid beta protein mediates
show dual trophic and toxic effects. The small common
region was reported to be antagonistic to the tachykinin
peptides, which can be neurotransmitters.
In other types of dementia such as in Parkinson’s disease
(PD), toxicity has been associated with Lewy bodies, which
are abnormal aggregation of proteins that interfere with
normal electrochemical signaling within the brain [5].
Alpha-synuclein has been suggested to be the primary
protein associated with Lewy bodies and has been tied to
mutations and/or over-expression of the gene [5].
Neural disorders are not always caused by neurodege-
nerative diseases. The brain can sustain physical injury
and also, from the administration or exposure to chemi-
cals. An example of physical injury is traumatic brain
injury (TBI), which is of particular concern for athletes or
victims of motor vehicle accidents. TBI could result in
lasting deficits due to brain damage. Cerebral vascular
accidents (CVA), otherwise known as stroke, can also
occur in patients leaving them with focal neural deficits.
However, the brain is also susceptible to various chemical
substances, including those currently used in standard
medical practice. Of particular focus are anesthetics.Intranasal administration of the anesthetic isoflurane,
has been suggested to decrease neurogenesis, primarily in
the hippocampus and dentate gyrus in young Wistar rats
[6]. In vitro studies suggested that particular doses of
isoflurane do not induce death of NSCs but decreased their
self-renewal property [6]. NSCs exposed to anesthetic
expressed lower levels of the stem cell-associated gene,
Sox2, suggesting evidence of NSC differentiation [6].
Therapies - neural disease
The current methods to treat neurodegenerative diseases
show little success. One of the main hurdles involves the
delivery of efficacious levels of the drug to the central
nervous system (CNS). The blood brain barrier (BBB)
could be selective with regards to molecules, including
drugs, crossing the barrier. Thus, there is a need to
develop less invasive, but efficacious treatments that can
bypass the hurdles associated with crossing the BBB to
treat brain disorders.
The BBB regulates the passage of nutrients, ions, and
other substances from the blood into the brain To cross
the BBB effectively, the molecule should be less than
400 Da, lipid soluble with less than 8–10 hydrogen bonds
with water as a solvent, and not be a substrate for an active
efflux transporter at the BBB such as p-glycoprotein [7].
Efflux transport systems may target the drugs that meet
these criteria and export them from the brain. As a result,
the BBB excludes many small-molecules, and nearly all
biopharmaceuticals such as gene and protein medicines,
which fail to penetrate into the brain tissue to an appre-
ciable extent [7]. To overcome the problem of delivering
drugs to the brain, multiple strategies have been developed,
as discussed in this review.
Memantine, a non-competitive antagonist to the N-
methyl-D-aspartate receptor (NMDA) receptor, showed
little benefit for AD [8]. Non-invasive procedures can be
used for certain diseases such as hemorrhagic ischemic
stroke [9]. Patients with ischemic stroke are usually
treated with tissue plasminogen activator (tPA) to in-
crease blood flow to the oxygen deprived brain region.
This type of intervention could pose a great risk with
regards to generalized bleeding [9]. In contrast, patients
with TBI are given invasive treatment, although with
little improvement [10].
In AD, the evidence indicated that reduced levels of the
neurotrophic brain-derived neurotrophic factor (BDNF)
could be attributed to the neurodegeneration. The adminis-
tration of BDNF in experimental models of this neuro-
degenerative disorder showed that this could slow the
process of neural degradation [11,12]. Due to the diffi-
culty of crossing the BBB, the treatment with BDNF
was delivered by intracranial injection. However, this
method might not be practical for humans with neuro-
degenerative diseases. Other methods to deliver BDNF
Aleynik et al. Clinical and Translational Medicine 2014, 3:24 Page 3 of 10
http://www.clintransmed.com/content/3/1/24are under investigation. These include the delivery in
BDNF in nanoparticles as well as ectopic expression of
BDNF in stem cells. The application of stem cells to
deliver drugs is discussed later in this review article.
Non-stem cell approaches
The intravenous administration route and the BBB may
be bypassed with intracerebral, intrathecal and intrana-
sal route of delivery [13,14]. The BBB may be locally
and reversibly disrupted to enhance the delivery of che-
motherapeutic agents using microbubble facilitated
focused ultrasound (MB-FUS) [15-18]. Passage of drugs
through the blood brain barrier may be facilitated through
chemical modifications to increase lipid solubility, plasma
half-life, mask enzyme cleavage sites, and chemical con-
jugation strategies to target specific transport systems,
receptor-mediated endocytosis/transcytosis, and adsorp-
tive endocytosis/transcytosis [19,20]. The passage of drugs
through the BBB may be improved through biological
modifications of drugs involving the coupling of the drug
to a receptor-targeted delivery vector such as a genetically
engineered peptidomimetic monoclonal antibody [21-24].
Drug passage through the BBB may also be facilitated
through novel strategies including encapsulation of thera-
peutic cells and their implantation into the surgical cavity,
convection-enhanced drug delivery, direct perilesional
injections, synthetic carriers such as metallic nanoparti-
cles, and gene therapy [13,19,21,25-29].
Invasive and non-invasive approaches were proposed to
deliver drugs to the brain to treat GBM. Intracranial injec-
tion, intraventricular administration and the disruption of
the BBB are examples of invasive delivery techniques used
during neurosurgery. This method could however resulted
in unwanted side effects such as disruption of the BBB,
which is linked to chronic neuropathologic changes [30]. A
gentler approach involves carrier- and receptor-mediated
transport mechanisms using endogenous nutrient trans-
port systems within the BBB (Figure 1). Carrier-mediated
transport utilizes stereospecific molecular carriers or pores
present on the apical and basolateral sides of the blood–
brain barrier to carry small molecules such as ions, energy
sources and amino acids [24]. Carrier-mediated transport
systems can be used for noninvasive drug delivery by
conjugating therapeutics to the natural substrates [24].
However, carrier-mediated transport will not work for
large molecule drugs [7].
Receptor-mediated transport (RMT) mechanisms can be
used to deliver larger molecules through the endogenous
vesicular trafficking system of the brain endothelium such
as the insulin, transferrin, or leptin receptor for brain influx
of nutrients through a transcellular, receptor-mediated
transport mechanism known as transcytosis [24]. Before
therapeutics can be delivered through RMT, the drug must
first be conjugated to a Molecular Trojan Horse (MTH)-amolecule that can target the natural RMT system [7]. RMT
transport has significantly less size restrictions than carrier
mediated transport due to a vesicle-based rather than a
stereo selective pore-based delivery mechanism [7]. It is
also important to note that RMT systems, which employ
the vesicular trafficking machinery of the endothelium to
transport substrates between blood and brain, have been
proven to work in vivo [7].
The delivery of a neuropharmaceutical across the BBB
through a receptor-mediated transport system requires
linkage to the BBB delivery vector that targets a known
blood-barrier receptor such as the transferrin receptor or
the insulin receptor [31]. The neuropharmaceutical can be
linked to the targeting vector either covalently or non-
covalently and can be conjugated to its targeting vector
through various methods including chemical linkage or
non-covalent steptavidin/biotin linkage [32]. The highest
priority for any conjugation strategy is to ensure that
neither the transport vector nor the pharmaceutical pro-
duct lose their function [32]. Chemical linkage strategies
may involve linking the pharmaceutical drug to the target-
ing vector using lysine residues of either the targeting
vector or the protein followed by chemical functiona-
lization using Traut’s reagent, maleimide, and chemical
spacer [33]. Non-covalent streptavidin/biotin linkage can
involve monobiotinylation at lysine residues using N-
hydroxysuccinimide (NHS) analogs of biotin, biotin hydra-
zide which reacts with carboxylic acid moieties on gluta-
mate and aspartate residues, or through a thioester linkage
between streptavidin and the targeting vector [34].
Alternative mechanisms for drug delivery through the
BBB can involve liposomes and nanoparticles [28]. Lipo-
somes can entrap water-soluble molecules in their aque-
ous core, absorb lipophilic drugs in their lipid bilayer
membrane, complex with gene-based medicines, become
more specific by coating with a BBB-targeting antibody,
and become less resistant to removal by the reticulo-
endothelial system (RES) through the incorporation of
PEG-disteraroyl-phosphatidylethanolamine (DPSE) moi-
eties into the liposome bilayer [31]. Nanoparticles such
as PBCA poly (butyl cyanoacrylate) can also be used to
deliver neuropharmaceuticals to the brain by entrapping
them in the nanoparticle matrix or attaching them to
the surface of the nanoparticle [34].
MSCs - cellular delivery of therapeutic agents
Stem cells are at the forefront in drug delivery, including
the transfer of RNA to treat neurodegenerative disorders
and brain tumors. Stem cells such as MSCs have been
shown to cross the BBB [35,36]. This property provides
stem cells with the advantage to overcome the current hur-
dles of delivering drugs to the brain. Despite a large num-
ber of methods to get drugs through the BBB, the method
remains inefficient. MSCs are an intriguing delivery system
Figure 1 Transport mechanisms across the blood brain barrier (BBB) are depicted. I) Shows receptor-mediated transport, II) demonstrates
non-specific uptake through adsorption-mediated transport, and III) displays carrier-mediated transport.
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the BBB they can home to regions of tumor growth for tar-
geted drug delivery [38]. MSCs could also serve as neuro-
protectants [39]. In order to understand the benefit of
MSCs, we first describe their basic biology, including their
origin and immune functions.
The origin of MSCs in adults is a subject of debate. It
is believed that MSCs are neuroectodermal. MSCs have
shown ease with regards to differentiate into cells of all
germ layers [40]. In general, the literature on stem cells
is mainly focused on their ability to regenerate and
protect tissues. There is relatively reduced emphasis on
the ability of stem cells, such as MSCs, to be applied as
cellular vehicle to deliver drugs across the BBB [41].
MSCs can be licensed to be immunosuppressor cells
when they are placed within an inflammatory milieu and
also when they are incubated with cytokines [42]. MSCs
express chemokine receptors, which provide them with
the ability to home to areas of tissue injury with a high
level of chemokines [43]. It is unclear if a particular
subset of MSCs has preference for homing to the sites of
tissue injury. The selection of MSCs, based on the
expression of chemokine receptor, could be an approach
to select the population that shows preference for ho-
ming to the site of tissue insults and tissue degeneration
[44]. Upon homing to the target site, MSCs can interact
with the ligands found in the tissue for specific immune
response. These types of responses are important for
tissue repair and protection.
The pathotropic effects of stem cells to home to
regions of tissue pathology underscores why the area of
stem cell therapy are gaining attention for brain dis-
orders. The use of stem cells to deliver drugs and RNA
need to be tried for disorders that would otherwise have
poor outcome [44]. Table 1 shows examples of clinical
and experimental trails using MSCs.MSCs have advantages over other stem cells with
regards to their use in cell therapy. MSCs can be easily
expanded from tissues with little ethical concerns. While
NSCs might be required to be obtained from autologous
source, MSCs can be used across allogeneic barrier.
Among the clinical trials studied, there is no evidence
that MSCs can survive for prolonged period. There are
other issues with MSCs when used to deliver drugs to
brain cancer such as their supporting roles for tumors.
This is a major issue and is therefore discussed in the
next section.
MSC therapy for brain pathologies
One area of study where MSC-based treatment has
gained traction is for brain tumors, in particular gliomas,
which represent the most common tumor of the brain.
GBM is associated with low survival rates. It is difficult
to treat GBM, partly due to the problems of transporting
the drugs through the BBB. To overcome this hurdle,
MSCs have been proposed as a method to use stem cells
to deliver drugs for gliomas.
MSCs are especially useful for their pathotropism, which
is their propensity to home at tumor sites. Stem cells
loaded with carboxylesterase were used as a method to
target tumor cells due to the ability of the enzyme to con-
vert a prodrug into an active form [51]. An experimental
study with rats genetically engineered MSCs to express
“suicide genes” to target glioma. The engineered MSCs
homed to glioma where they inhibited the glioma cell
growth to improve the survival of the animal [52]. MSCs
can be used to deliver miRNA mimics to target gliomas.
MSCs transfected with miRNA-124 and miRNA-145
mimics inhibited the migration of glioma cells [53]. The
aforementioned preclinical trials provided evidence that
MSC-mediated delivery of therapeutic factors will soon be
incorporated into clinical trials.
Table 1 Clinical and experimental therapies with MSCs for neural-related diseases
Diseases Cells Study References
Glioblastoma multiforme MSC-Gene therapy Experimental/Murine [45]
Glioblastoma multiforme MSCs: miRNA Experimental/Murine [46]
Glioblastoma multiforme Gene therapy: (hsFlt3L/TK) Experimental/Dog [47]
Multiple Sclerosis MSCs Clinical Trial NCT01883661
Experimental Autoimmune Encephalitis MSCs Experimental/Mouse [48]
Parkinson’s Disease MSCs Clinical Trial NCT01446614
Alzheimer’s disease MSCs Human NCT01547689
Amyotrophic Lateral Sclerosis MSCs Experimental/Murine [49]
Huntington’s Disease MSCs Experimental/Mouse [50]
The table shows representative clinical and experimental trials with MSCs.
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disorders such as AD and multiple sclerosis have seen
encouraging results from the research on MSC-mediated
delivery of therapeutic agents. MSCs have been thought
to promote remyelination in multiple sclerosis (MS), and
to prevent degradation of existing myelin. In experimen-
tal studies, MSCs have proven to enhance remyelination
when co-transplanted with oligodendrocyte precursor
cells (OPC) [54]. The transplantation of OPCs alone was
not sufficient to treat MS since these cells express allo-
antigens and could be subjected to immune rejection.
To overcome immune rejection, OPCs could be co-
transplantated with MSCs. The latter could thwart allor-
ejection based on their immunosuppressive characteris-
tics as well as their ability to home to the site of injury.
The results showed that co-transplantation of MSCs
increased the maturation of oligodendrocyte, myeli-
nation in the corpus callosum, and decreased the
immune reaction from microglia and astrocytes.
MSCs can be ectopically expressed to secrete specific
factors after homing to the brain for disorders such as MS.
MSCs were genetically engineered to secrete IFN-β, which
was shown to inhibit the effects of pro-inflammatory cyto-
kines to ameliorate the symptoms of MS [55]. The precli-
nical successes have led to current studies to test the
safety of autologous and allogeneic MSC transplantation,
although most of those studies are in the recruiting stage.
The large number of preclinical trials indicated that
MSC-mediated therapy show promise for cellular the-
rapy. However, there are some concerns that have been
expressed with the use of MSCs to deliver drugs, based
on the disease. For example, in the case of gliomas, these
are heterogeneous diseases. More importantly, there are
noted differences in gliomas in rodent models and
humans. There are concerns that these differences could
impact clinical trials [56]. Most noted are the models of
human GBM that are developed in immune deficient
mice. Despite the route of injection intracranially, the
microenvironment might be similar as the human brain,but the mice lacks an immune system. Histopathology of
the experimental and human tumors showed significant
differences. Another issue is that many studies injected
GBM in the dorsal flanks of mice, which do not reca-
pitulate GBM in human.
In addition to the questions regarding efficacy, there
may also be concern for safety, as some studies have noted
formation of tumors in MSC cultures from mice, and
evidence of cell death due to inflammation and reactive
oxygen species [57]. The rare reports of transformation
reported for murine MSCs have not been noted for
human. More importantly, MSCs can support the same
tumors that they target for drug delivery [58]. Research
studies are needed to determine how a suicide gene can
be invoked to eliminate the MSCs after drug delivery.
Despite the possible side effects, there are several on-
going clinical trials with MSCs as a delivery method for
the treatment of a number of brain pathologies including
brain ischemia, Amyotrophic Lateral Sclerosis (ALS), MS,
and AD. Studies have also shown that it may be possible
to use MSCs for the delivery of therapeutic agents to
gliomas through the release of exosomes [46]. Since exo-
somes are rich sources of miRNAs, which could be the
future method of therapies, it is important to include a
discussion on exosomes in this review article.
Exosomes for miRNA delivery via stem cells
This section discusses the biogenesis of exosomes and
the composition because their release could be used as a
method to transfer small miRNA from MSCs to the
brain tumors and also to treat neurodegenerative
disorders. Indeed, RNA-loaded MSCs can deliver small
RNA through gap junction and by their package in
exosomes [46,59].
Exosomes or microvesicular bodies (MVBs) are membrane-
bound nanoparticles, ranging between 30–100 nm in
diameter [60]. The vesicles are at times considered as
endosomes that fuse with the plasma membrane. Exo-
somes are released by various cell types such as immune
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cells, tumor cells, neurons, and MSCs [61,62]. The
exosomes are small vesicle-like structures that transport
proteins, lipids, mRNAs, and miRNAs [60]. Exosomes
play an important role in intercellular communication and
have been described to regulate immune functions, tumor
migration and modulate the actions of drugs [32].
There is increasing evidence that exosomes are present
in physiological fluids such as plasma and pleural effu-
sions and urine from malignancy [63]. Exosomes have
also been proposed as novel systems for the delivery of
therapeutic agents [64]. An understanding of exosome
biogenesis and composition will help to advance our
understanding on the mechanisms by which MSCs are
used in therapeutic applications.
Exosomes originate as endosomal intraluminal vesicles
(ILVs) or MVBs that undergo endocytic fusion with the
plasma membrane to release 50–90 nm intra-luminal
vesicles into the extracellular milieu [65]. As an alterna-
tive fate, ILVs or MVBs can sequester proteins destined
for degradation in lysosomes. The internal membranes
of MVB contain cholesterol-rich membranes [66]. In
addition, detergent-resistant membranes containing well-
characterized raft marker proteins such as GPI-anchored
proteins and flotillin have been isolated from the detergent
resistant membranes of late endosomes [67]. These data
suggested that lipid raft components in the endosomal
system are sorted to the internal membranes of multi-
vesicular bodies [68]. In proteomic and biochemical
analyses of exosomes, an enrichment of several raft pro-
teins and lipids was observed [68]. These observations
suggested a connection between MVB and immune
responses [68]. In fact, it appears that HIV budding in
primary macrophages occurs through the exosome release
pathway [68]. By budding through lipid rafts in T-cells,
HIV selectively incorporates raft markers and excludes
non-raft proteins. These findings are in agreement with
results that indicate the involvement of rafts in the inter-
action of HIV with host cells [68].
MiRNAs
The influence of exosomes on the stem cell microenviron-
ment and ensuing cellular function has also been studied
within the context of miRNA. The exosome-containing
miRNAs can modulate functional changes when trans-
ferred to cells. MiRNAs are small (18–24 nucleotides) en-
dogenous non-coding RNAs that act as post-transcriptional
regulators of gene expression and thus play crucial roles in
regulating multiple cellular processes [69]. MiRNAs are
first synthesized as primary transcripts, referred as pre-
miRNAs [69]. These structures are then processed as
pre-miRNAs by the nuclear protein DGCR8 and the
ribonuclease Drosha before exported to the cytoplasm
via exportin-5 [70]. Pre-miRNAs are further modified bythe RNase III enzyme Dicer to form mature double-
stranded miRNA duplexes [55,56]. Argonaute proteins
then associate with these duplexes to create the miRNA-
induced silencing complex (miRISC) that acts as the ma-
chinery by which miRNAs can regulate the translation of
transcript targets.
MiRNAs can cause degradation or translational re-
pression of mRNA to negatively regulate more than 30%
of the genes to control cell proliferation, inflammation,
and metabolism. Thus, miRNA could be involved in the
deregulation of key signaling cascades to disrupt cellular
homeostasis and induce carcinogenesis, such as GBM
[71]. The biological functions of miRNAs are highly
significant to the treatment of brain disorders.
MiRNAs are involved in the development and progres-
sion of brain tumor [46,71]. There are several reports on
the literature on miRNAs in tumor development. Similar
to most pathological system, the role of miRNAs is com-
plex. On a more general function, miRNAs are involved
in the regulation of genes with oncogenic and tumor-
suppressive properties [72].
Studies on miRNA in GBM and other neurodegenerative
disorders are important to future therapy with RNA. This
would require efficient delivery of RNA across the BBB. As
examples, miRNAs and antagomiRs can target specific mo-
lecules within the signaling pathways caused by the activa-
tion of specific receptors within the disease. In the case of
GBM, the receptor tyrosine kinase epidermal growth factor
receptor (EGFR) is activated to promote cell growth, resis-
tance to apoptosis, adhesion and cell migration [73]. MiR-
NAs inhibited the signaling of EGFR in GBM by blunting
the signaling networks involving PI3/Akt pathway [74]. This
resulted in chemosensitization of the frontline treatment
for GBM, TMZ. MiRNAs might function at multiple levels
since miR-21 and miR-26 appeared to be involved in the
increased expression of EGFR and decreased the tumor
suppressor gene, PTEN [75,76]. EGFR is overexpressed in
40-60% of primary GBM tumors and this subset of GBM
results in worst prognosis [73,75]. Thus, the identification
and efficient delivery of miRNAs would be significant for
EGFR-expressing GBM.
MiRNAs can also prevent GBM progression and deve-
lopment by differentially regulating the expression of key
genes in brain tumors. MiR-218 and miR-326 have been
reported to decrease IκB kinase thereby inhibiting the ac-
tivation of NF-κB [77]. MiR-326 has been shown to regu-
late the Notch signaling in GBM [78]. The evolutionary
conserved miR-9 could also be targeted. However, caution
has to be exerted due to its additional neuroprotective
function [46,79]. Table 2 outlines how representative
miRNAs can regulate key signaling molecules, sugges-
ting potential targets for GBM. Regardless of the identi-
fication of targets for GBM or other brain pathologies,
the delivery of miRNA and other therapeutics must first
Table 2 MiRNAs and key molecules in signaling pathways reported for gliobastoma multiforme
Target miRNA Pathway/Process References
EGFR miR-7 EGFR signaling [80]
PTEN miR-21 Cell-cycle progression, Apoptosis [75]
PTEN miR-26a Akt pathway [76]
Notch1/Notch2 miR-326 Notch pathway [78]
IκB miR-218 IKK-β/NF-κB pathway [77]
STAT1/STAT2 miR-221/miR-222 IFN-α signaling pathway [81]
CDK6 miR-124/miR-137 Cell cycle arrest [82]
Bmi-1 miR-128 Bmi-1 decrease [83]
Akt1, CyclinD1, MMP-2, MMP-9, Bcl-2 miR-451 Tumor suppression [84]
Table shows representative examples of how specific molecules are regulated by miRNAs, and to provide insights on how the information can be used to develop
treatment strategies.
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issue is discussed throughout the text since it is funda-
mental to brain therapies.
Overall, the discussion in this section when combined
with the previous section on exosomes, showed that
exosomes could be designed with the intent to deliver
specific miRNA. A method by which this could occur is
to express the desired miRNA in MSCs. The miRNAs
can then be packaged as exosomes. The MSCs, which
can cross the BBB, would then release exosomes within
the brain. This method is advantageous as it will bypass
the BBB to deliver small RNA to the brain. The method
could be therapeutic in altering biological processes [60].Figure 2 MSCs genetically engineered to secrete IFN-β injected into t
U87 glioblastoma cells within the central nervous system (CNS). Adm
vein or subcutaneously does not lead to penetration of the BBB or MSC tu
ligand combinations and is correlated with bulk tumor size reduction.Stem cell as a vehicle of drug delivery
Although discussed above, this section revisits the use of
MSCs and discusses the advantages of these stem cells for
drug delivery. MSCs are inherently immunosuppressive
and have the ability to home to a variety of primary and
metastatic tumors including breast, colon, ovarian, lung
carcinomas, as well as gliomas [38]. An examination of the
clinical trial registry (clinicaltrials.gov) indicates that MSCs
are prominent for drug delivery in cancers, including ova-
rian, prostate, head and neck as well as hematological ma-
lignancies. MSCs can be expressed to deliver cytokines,
prodrugs, apoptosis inducing proteins, and anti-angiogenic
agents [85-92]. These findings have to be considered withhe rat internal carotid artery can penetrate the BBB and home to
inistration of these genetically engineered MSCs through the rat’s tail
mor homing. This tropic mechanism is mediated by several receptor
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tumorigenic effects and that MSCs should be reliably
tracked once administered [38].
MSC delivery of therapeutic agents can overcome
obstacles related to anatomical barriers, drug half-life,
and tumor targeting [86]. Cytokines with anti-tumor
properties such as IL-2, IFN-β, and tumor necrosis
factor-related apoptosis-inducing ligand (TRAIL) have
limited utility due to a short half-life in vivo and their
toxic effect on normal cells [93]. A major advantage for
using MSC as cytokine delivery vehicles is the ability of
MSCs to selectively migrate to the tumor site and release
the intended agent [93]. In addition to MSCs selectively
homing to solid tumors they also actively home to sites of
metastases, distant from the primary tumor [33].
Due to the problems of getting drugs through the
BBB, GBM could be an ideal cancer for MSCs in drug
delivery [24,25]. Despite decades of research and
advances in the treatment of this disease with surgery,
radiotherapy, and chemotherapy, there is no cure and
the current prognosis gives a median survival of only
12–18 months [25,33]. Current therapies fail to cure the
disease due to the inability to selectively target tumor
cells, which have disseminated into the normal paren-
chyma of the brain, at sites distant from the tumor mass
[25]. MSCs have the potential to provide neurotrophic
support and deliver therapeutics to sites of brain pa-
thology after intra-arterial administration, implantation
directly into the tumor bed, implantation at a distant
intracranial site from the tumor bed in the same hemi-
sphere or collateral hemisphere, implantation into brain
ventricles, or implantation into a peripheral intravascular
site as confirmed by studies in rodents [94,95]. In a
recent experimental study with GBM, MSCs have been
shown to home to the solid tumor through tropic me-
chanisms, as outlined in Figure 2 [95]. This tropism
could be mediated by several receptor-ligand combina-
tions, which is correlated with reduced tumor burden
[95]. While the migratory properties of MSCs are intri-
guing, it is also important to note that MSC-based treat-
ments could also support tumor growth [38,96].
Conclusion
MSCs have the potential as cellular vehicles for drugs
and other molecules to treat patients with neural dis-
eases such as GBM, AD, PD, TBI and other neuropatho-
logies for which limited treatment options exist. When
considering the limitations of current methods of drug
delivery to the brain, MSCs have the potential to become
a safe cellular delivery vehicle containing a prodrug as
well as ectopically expressed genes for targeted delivery.
The affinity for MSCs to migrate to the brain combined
with the relative ease for expanded MSCs make them
attractive for gene and drug delivery.Abbreviations
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